I manage CE‑marking and post‑market surveillance for Class IIa/IIb devices. Over the last five years I’ve watched more than one promising SME start a Technical File only to stop when the cost and complexity rose past their runway. This isn’t a single cause — it’s a compound of MDR requirements, notified‑body availability, and realistic evidence expectations. I’ll be blunt: MDR was supposed to protect patients and harmonise the market. To be fair, it does that in principle. In practice this means rising fixed costs that disproportionately hit small teams.
Where the budget pressure comes from
Several MDR elements repeatedly create hard, early cost inflection points for SMEs:
- Annex II (Technical Documentation): the detail expected in device description, design and manufacturing information, and risk management is deeper and more granular than before. Drafting a defendable Technical File is staff‑intensive or expensive to outsource.
- Annex IX / conformity assessment: fewer notified bodies, longer timelines, and more extensive audit scope. Longer time to certificate equals longer time to revenue.
- Clinical evidence expectations (Article 61 and MDCG guidance): equivalence claims are scrutinised and PMCF requirements in Annex XIV are real workstreams, not checkboxes.
- Post‑market requirements (PSURs, vigilance, periodic safety reporting): ongoing resource needs rather than one‑off costs.
- Notified‑body unpredictability: differing interpretations of the same clause force repeat work and extra studies.
None of the above is novel reading, but the cumulative effect is what matters. A small team faces simultaneous needs for technical documentation, a robust QMS (ISO 13485 aligned), clinical follow‑up, and an audit‑ready system. The cheapest path — cut corners — is also the quickest route to a nonconformity during NB audit.
Real trade‑offs I’ve seen SMEs make (and why they often fail)
- Delay market entry to raise funds. That buys time but not certainty: the regulatory bar moves and costs rise while you wait.
- Narrow the intended use to avoid higher classifications. This helps, granted, but classification pitfalls and borderline features can undo the plan at audit.
- Hire consultants to "get it over the line." Consultants help, but they add cost and hand‑offs create traceability gaps unless you rigorously manage the interface.
A particularly common failure mode: an SME pays for a clinical equivalence justification, the NB requests an additional PMCF study design, and now the budget must stretch to a small observational study plus CRF management, CRO oversight, and data cleaning. Those costs are not trivial and they compound with the direct NB fees.
What I do differently when budgets are small
When I work with constrained teams I push for surgical prioritisation and pragmatic evidence planning — not minimalism, but realism:
- Prioritise the markets and SKUs that matter. EU-wide coverage is attractive, but start where you can realistically get notified‑body time and early reimbursement.
- Focus Technical Files on traceable substantiation. Annex II requires evidence; a traceable matrix that links claims to design outputs, risk controls, and clinical data saves hours during audits.
- Reuse valid data, but satisfy MDCG: equivalence can work if the justification is airtight. In practice this means thorough device/component comparison tables and access to unredacted data where needed.
- Design PMCF that answers specific residual risks, per Annex XIV. Broad, expensive studies that attempt to prove everything rarely fit early budgets. A targeted registry or pragmatic cohort can often be defensible.
- Make the QMS work for you: invest in tools that provide change impact analysis, connected workflows for CAPA and risk, and reviewability for audit trails. The tool should reduce administrative friction, not add it.
Software and process choices that actually reduce cost
I am pragmatic about eQMS. Features that matter for an SME under MDR:
- Document traceability that links requirements (MDR/Annex sections), risk controls, and clinical evidence.
- Change impact mapping so a design change shows all affected procedures, files, and pending CAPAs.
- PMCF and PSUR workflows that create structured artefacts rather than free‑text notes — this saves outsourced study time.
- CAPA workflows that enable automated CAPAs with reviewability and clear assignment, so issues don’t pile up.
To be clear: software isn’t a silver bullet. It reduces repetitive labour and improves audit readiness, which translates to lower external costs, but it requires discipline and the right configuration.
Where regulators and notified bodies could help (my wish list)
- More consistent guidance on equivalence and PMCF expectations across notified bodies.
- Faster, clearer decisions on borderline classification to avoid late surprises.
- Templates or harmonised matrices for demonstrating traceability from claim to evidence under Annex II.
To be fair, there are pockets of good practice. Some notified bodies publish detailed questions and checklists that help SMEs prepare. But not every NB does this, and the inconsistency is a real burden.
Final thought
The result is a market where capital‑rich firms can absorb the rising baseline costs and smaller innovators are forced to choose between a costly pivot or leaving the EU. That outcome worries me because it reduces competition and limits patient access to novel devices.
What pragmatic changes have you made to keep a small device programme financially and regulatorily viable under MDR?
Top comments (0)